重组人干扰素内皮抑制肽融合蛋白抗肿瘤药效的研究

Study on Antitumor Effect of Recombinant Human Interferon Endothelial Peptide Fusion Protein

目的考察融合蛋白I30肽抗肿瘤的效果,为I30肽后续开发提供实验支持。方法使用NIH小鼠,取4只小鼠腹腔注射H_(22)瘤株,1周时处死所有小鼠,取腹水。另取40只小鼠,每只腋下注射腹水0.2 mL,细胞浓度为1×10~6个/mL。接种后4 h开始给药。将腋下注射小鼠随机分为4组:IFN组,皮下注射干扰素9×10~5IU/只;I30高剂量组,皮下注射I30 80μg/只;I30低剂量组,皮下注射I30 30μg/只;阴性对照组,皮下注射等体积生理盐水。连续给药16 d。停药后2 h,处死所有动物,再解剖皮下瘤块称重。结果 I30给药组具有明显的治疗效果,且具有显著性差异(P<0.05)。结论 I30肽具有抗肿瘤的作用。

Objective To investigate the antitumor effect of I30 peptide, and to provide experimental result for the further development of I30 peptide. Method Using NIH mouse, 4 mice were injected intraperitoneally with H22 tumor strain, and all mice were sacrificed at 1 week, and ascites was extracted. Another 40 mice were injected with 0.2 mL ascitic fluid, and the cell concentration was 1×10^6个/mL. At 4 h after inoculation mice were treated in different groups. The mice were divided into 4 groups randomly, IFN group, subcutaneous injection of interferon 9×10^5 IU/mL;I30 high dose group, subcutaneous injection of 80 μg/I30;I30 low dose group, subcutaneous injection of 30 μg/I30;negative control group, subcutaneous injection of normal saline. Mice were continuous administrated for 16 d. After 2 h, all animals were sacrificed, and the subcutaneous tumor mass was dissected. Result The treatment group had obvious therapeutic effect, and the difference was significant(P<0.05). Conclusion I30 has anti-tumor effect.